Annexon, Inc. (NASDAQ:ANNX) Given Average Recommendation of “Hold” by Analysts

Shares of Annexon, Inc. (NASDAQ:ANNX) have been given a consensus rating of “Hold” by the five ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $12.50.

A number of research firms have recently commented on ANNX. HC Wainwright restated a “buy” rating and issued a $14.00 price objective on shares of Annexon in a research report on Friday, August 15th. Zacks Research upgraded shares of Annexon from a “strong sell” rating to a “hold” rating in a research report on Monday, August 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Annexon in a research report on Wednesday.

Institutional Investors Weigh In On Annexon

Hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP lifted its stake in Annexon by 1.8% during the 4th quarter. Wellington Management Group LLP now owns 268,166 shares of the company’s stock valued at $1,376,000 after acquiring an additional 4,806 shares during the period. Hsbc Holdings PLC increased its holdings in Annexon by 19.9% in the 1st quarter. Hsbc Holdings PLC now owns 36,935 shares of the company’s stock worth $73,000 after acquiring an additional 6,136 shares in the last quarter. Jane Street Group LLC increased its holdings in Annexon by 8.2% in the 1st quarter. Jane Street Group LLC now owns 99,924 shares of the company’s stock worth $193,000 after acquiring an additional 7,553 shares in the last quarter. Matauro LLC purchased a new stake in Annexon in the 2nd quarter worth approximately $27,000. Finally, CWM LLC grew its holdings in Annexon by 212.9% during the 2nd quarter. CWM LLC now owns 17,734 shares of the company’s stock valued at $43,000 after buying an additional 12,066 shares in the last quarter.

Annexon Stock Performance

ANNX opened at $3.26 on Friday. The firm has a market cap of $358.24 million, a P/E ratio of -2.53 and a beta of 1.36. The firm has a 50-day moving average of $2.54 and a 200 day moving average of $2.28. Annexon has a fifty-two week low of $1.28 and a fifty-two week high of $7.85.

Annexon (NASDAQ:ANNX) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.02. Equities research analysts predict that Annexon will post -0.96 earnings per share for the current fiscal year.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.